Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy

Inclusion Criteria:

* Patients with histologically-confirmed follicular lymphoma CD20-positive grade 1, 2 ó 3a.
* Patients with aptitude to sign the written informed consent and to express his desire to fulfill all the requirements of the protocol during the period of study.
* Patients not treated before. The induction treatment with rituximab and chemotherapy must be the first line for the patients who are included in the study.
* Patients undergoing maintenance therapy with rituximab every two/three months.
* Ann Arbor stage II, III o IV before receiving the induction treatment with rituximab and chemotherapy.
* The patient must have achieved a partial or complete response based on the revised International Workshop Response Criteria (IWRC) (Cheson, et al 2007) following the induction treatment.
* Age \>18 years and \<75 years.
* Performance status \<2 following the Eastern Cooperative Oncology Group (ECOG).
* Screening laboratory values obtained 28 days before registry (unless due to lymphoma involvement of the bone marrow): Hemoglobin \> 8,0 g/dL (5,0 mmol/L), Neutrophil absolute count \> 1,5 x 109/L,Platelets \> 100 x 109/L

Exclusion Criteria:

* Patients with transformed follicular lymphoma into diffuse large B-cell lymphoma.
* Patients with evidence of follicular lymphoma grade 3b.
* Patients with evidence of primary cutaneous or gastrointestinal follicular lymphoma.
* Patients with evidence of current central nervous system involvement.
* Patients who received previous induction treatment other than rituximab and chemotherapy.
* Patients receiving chronic immunosuppressive agents in the last 4 weeks. Patients may be receiving stable chronic doses of corticosteroids with a maximum dose of 20 mg/day of prednisone or equivalent.
* Patients who have a history of another primary malignancy \< 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix.
* Decompensated renal function: serum creatininea \> 2,0 mg/dL (197 u.mol/L.
* Decompensated hepatic function: total bilirrubine \> 2,0 mg/dL (34 umol/L), AST (SGOT) \> 3 x ULN, unless due to lymphoma involvement
* Patients with a known history of human immunodeficiency virus (HIV) seropositivity, chronic hepatitis or other active viral infections due to hepatitis B virus (HBV) or hepatitis C virus (HVC).
* Patients with underlying serious diseases that in the criteria of the investigator could concern the capacity of the patient to take part in the test (for example, infection in process, not controlled diabetes mellitus, gastric ulcers, autoimmune active disease).
* Life expectancy \<6 months.
* Female patients who are pregnant or breast feeding.
* Patients with known hypersensitivity to rituximab or other murine proteins or to any of the excipients.
* Patients who are using other investigational agents or who have received investigational drus 30 days prior to study drug start.
* Any other medical or psychological coexistent condition that rejects the participation in the study or compromises the aptitude to give the informed consent.